This week, Oslo City Court upheld Intervet’s patent extension. If the verdict becomes final, Intervet will have the exclusive rights to sell vaccines against PD in Norway in the extended period from October 2015 to May 2020. The decision is therefore of great importance for Intervet.
There have been disputes related to Intervet’s patent between the Parties since 2008. Pharmaq has previously both claimed compulsory license and attacked the validity of the patent.
Intervet has so far been successful in all disputes raised by Pharmaq concerning the patent. Thommessen assisted Intervet throughout all these disputes.
Intervet is owned by MSD Animal Health, which is part of the Merck Group.